Document:

Supplemental Indenture dated June 8, 2010 Senior Subordinated Notes due 2014

 EXHIBIT 10.2 

SUPPLEMENTAL INDENTURE 

SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of
June 8, 2010, among Angiotech America, Inc. and Angiotech Florida Holdings, Inc. (each, a “Guaranteeing Subsidiary” and, collectively, the “Guaranteeing Subsidiaries”), subsidiaries of Angiotech
Pharmaceuticals, Inc. (or its permitted successor), a corporation organized under the Business Corporations Act of the Province of British Columbia (the “Company”), the Company, the other Guarantors (as defined in the Indenture
referred to herein) and Deutsche Bank National Trust Company, as successor to Wells Fargo Bank, N.A., as trustee under the Indenture referred to below (the “Trustee”). 

W I T N E S S E T H 

WHEREAS, the Company has heretofore executed and delivered to the Trustee an indenture (the
“Indenture”), dated as of March 23, 2006, providing for the issuance of 7.75% Senior Subordinated Notes due 2014 (the “Notes”); 

WHEREAS, the Indenture provides that under certain circumstances the Guaranteeing Subsidiaries shall execute and deliver
to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiaries shall unconditionally guarantee all of the Company’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein (the
“Note Guarantee”); and 
 WHEREAS, pursuant to Section 9.01 of the Indenture, the Trustee
is authorized to execute and deliver this Supplemental Indenture. 
 NOW, THEREFORE, in consideration of the
foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Guaranteeing Subsidiaries and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows:

 1. CAPITALIZED TERMS. Capitalized terms used herein without definition shall
have the meanings assigned to them in the Indenture. 
 2. AGREEMENT TO
GUARANTEE. The Guaranteeing Subsidiaries hereby agree to provide an unconditional Guarantee on the terms and subject to the conditions set forth in the Note Guarantee and in the Indenture including but not limited to Article 11
thereof. 
 3. NO RECOURSE AGAINST OTHERS. No past,
present or future director, officer, employee, incorporator, stockholder or agent of the Guaranteeing Subsidiaries, as such, shall have any liability for any obligations of the Company or any of the Guaranteeing Subsidiaries under the Notes, any
Note Guarantees, the Indenture or this Supplemental Indenture or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder of the Notes by accepting a Note waives and releases all such liability. The
waiver and release are part of the consideration for issuance of the Notes. Such waiver may not be effective to waive liabilities under the federal securities laws and it is the view of the Securities and Exchange Commission that such a waiver is
against public policy. 

 4. NEW YORK LAW TO GOVERN. THE INTERNAL LAW OF THE STATE OF NEW YORK SHALL
GOVERN AND BE USED TO CONSTRUE THIS SUPPLEMENTAL INDENTURE WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT THAT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY. 

5. COUNTERPARTS. The parties may sign any number of copies of this Supplemental Indenture. Each signed
copy shall be an original, but all of them together represent the same agreement. 
 6. EFFECT
OF HEADINGS. The Section headings herein are for convenience only and shall not affect the construction hereof. 

7. THE TRUSTEE. The Trustee shall not be responsible in any manner whatsoever for or in
respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Subsidiaries and the Company. 

 

 2 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental
Indenture to be duly executed and attested, all as of the date first above written. 
 Dated: June 8, 2010

  

			
	 ANGIOTECH FLORIDA HOLDINGS, INC.

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   Treasurer

	
	 ANGIOTECH AMERICA, INC.

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   Treasurer

	
	 ANGIOTECH PHARMACEUTICALS, INC.

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   SVP, Finance

	
	 AFMEDICA, INC.

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   Treasurer

	
	 AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.

		
	 By:
	 	 /s/ David D. Phinney

		 	 Name: David D. Phinney

		 	 Title:   Secretary

			
	 ANGIOTECH BIOCOATINGS CORP.

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   Treasurer

	
	 ANGIOTECH CAPITAL, LLC

		
	 By:
	 	 /s/ David D. Phinney

		 	 Name: David D. Phinney

		 	 Title:   Manager

	
	 ANGIOTECH DELAWARE, INC. (F/K/A
AMERICAN
MEDICAL INSTRUMENTS, INC.)

		
	 By:
	 	 /s/ David D. Phinney

		 	 Name: David D. Phinney

		 	 Title:   Secretary

	
	 ANGIOTECH INTERNATIONAL HOLDINGS, CORP.

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   President & Secretary

	
	 ANGIOTECH INVESTMENT PARTNERSHIP, by its
partners,

		
		 	 ANGIOTECH PHAMACEUTICALS, INC.

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   SVP, Finance

		
		 	 3091796 NOVA SCOTIA COMPANY

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   Director

			
	 ANGIOTECH PHARMACEUTICALS (US), INC.

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   SVP, Finance

	
	 BG SULZLE, INC.

		
	 By:
	 	 /s/ David D. Phinney

		 	 Name: David D. Phinney

		 	 Title:   Secretary

	
	 MANAN MEDICAL PRODUCTS, INC.

		
	 By:
	 	 /s/ David D. Phinney

		 	 Name: David D. Phinney

		 	 Title:   Secretary

	
	 MEDICAL DEVICE TECHNOLOGIES, INC.

		
	 By:
	 	 /s/ David D. Phinney

		 	 Name: David D. Phinney

		 	 Title:   Secretary

	
	 NEUCOLL, INC.

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   Treasurer

	
	 QUILL MEDICAL, INC.

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   Treasurer

			
	 SURGICAL SPECIALTIES CORPORATION

		
	 By:
	 	 /s/ David D. Phinney

		 	 Name: David D. Phinney

		 	 Title:   Secretary

	
	 SURGICAL SPECIALTIES PUERTO RICO, INC.

		
	 By:
	 	 /s/ David D. Phinney

		 	 Name: David D. Phinney

		 	 Title:   Secretary

	
	 SURGICAL SPECIALTIES UK HOLDINGS LIMITED

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   Secretary

	
	 0741693 B.C. LTD.

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   SVP, Finance

	
	 3091796 NOVA SCOTIA COMPANY

		
	 By:
	 	 /s/ Jay Dent

		 	 Name: Jay Dent

		 	 Title:   Director

	
	 DEUTSCHE BANK NATIONAL TRUST COMPANY,
as Trustee

		
	 By:
	 	 /s/ Katherine Cohic

		 	 Authorized SignatorySupplemental Indenture dated June 8, 2010 Senior Notes due 2013

 EXHIBIT 10.3 

SUPPLEMENTAL INDENTURE 

SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of
June 8, 2010, among Angiotech America, Inc. and Angiotech Florida Holdings, Inc. (each, a “Guaranteeing Subsidiary” and, collectively, the “Guaranteeing Subsidiaries”), subsidiaries of Angiotech
Pharmaceuticals, Inc. (or its permitted successor), a corporation organized under the Business Corporations Act of the Province of British Columbia (the “Company”), the Company, the other Guarantors (as defined in the Indenture
referred to herein) and Deutsche Bank National Trust Company, as successor to Wells Fargo Bank, N.A., as trustee under the Indenture referred to below (the “Trustee”). 

W I T N E S S E T H 

WHEREAS, the Company has heretofore executed and delivered to the Trustee an indenture (the
“Indenture”), dated as of December 11, 2006, providing for the issuance of Senior Floating Rate Notes due 2013 (the “Notes”); 

WHEREAS, the Indenture provides that under certain circumstances the Guaranteeing Subsidiaries shall execute and deliver
to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiaries shall unconditionally guarantee all of the Company’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein (the
“Note Guarantee”); and 
 WHEREAS, pursuant to Section 9.01 of the Indenture, the Trustee
is authorized to execute and deliver this Supplemental Indenture. 
 NOW, THEREFORE, in consideration of the
foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Guaranteeing Subsidiaries and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows:

 1. CAPITALIZED TERMS. Capitalized terms used herein without definition shall
have the meanings assigned to them in the Indenture. 
 2. AGREEMENT TO
GUARANTEE. The Guaranteeing Subsidiaries hereby agree to provide an unconditional Guarantee on the terms and subject to the conditions set forth in the Note Guarantee and in the Indenture including but not limited to Article 10
thereof. 
 3. NO RECOURSE AGAINST OTHERS. No past,
present or future director, officer, employee, incorporator, stockholder or agent of the Guaranteeing Subsidiaries, as such, shall have any liability for any obligations of the Company or any of the Guaranteeing Subsidiaries under the Notes, any
Note Guarantees, the Indenture or this Supplemental Indenture or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder of the Notes by accepting a Note waives and releases all such liability. The
waiver and release are part of the consideration for issuance of the Notes. Such waiver may not be effective to waive liabilities under the federal securities laws and it is the view of the Securities and Exchange Commission that such a waiver is
against public policy. 

 4. NEW YORK LAW TO GOVERN. THE INTERNAL LAW OF THE STATE OF NEW YORK SHALL
GOVERN AND BE USED TO CONSTRUE THIS SUPPLEMENTAL INDENTURE WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT THAT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY. 

5. COUNTERPARTS. The parties may sign any number of copies of this Supplemental Indenture. Each signed
copy shall be an original, but all of them together represent the same agreement. 
 6. EFFECT
OF HEADINGS. The Section headings herein are for convenience only and shall not affect the construction hereof. 

7. THE TRUSTEE. The Trustee shall not be responsible in any manner whatsoever for or in
respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Subsidiaries and the Company. 

 

 2 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental
Indenture to be duly executed and attested, all as of the date first above written. 
 Dated: June 8, 2010

  

			
	 ANGIOTECH FLORIDA HOLDINGS, INC.

		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    Treasurer

 

			
	 ANGIOTECH AMERICA, INC.

		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    Treasurer

 

			
	 ANGIOTECH PHARMACEUTICALS, INC.

		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    SVP, Finance

 

			
	 AFMEDICA, INC.

		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    Treasurer

 

			
	 AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.

		
	 By:
	 	       /s/ David D. Phinney
        

		 	 Name:  David D. Phinney

Title:    Secretary

			
	 ANGIOTECH BIOCOATINGS CORP.

		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    Treasurer

 

			
	 ANGIOTECH CAPITAL, LLC

		
	 By:
	 	       /s/ David D. Phinney
        

		 	 Name:  David D. Phinney

Title:    Manager

 

			
	 ANGIOTECH DELAWARE, INC.
(F/K/A AMERICAN
 MEDICAL INSTRUMENTS,
INC.

		
	 By:
	 	       /s/ David D. Phinney
        

		 	 Name:  David D. Phinney

Title:    Director

 

			
	 ANGIOTECH INTERNATIONAL HOLDINGS, INC.

		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    Director

 

			
	 ANGIOTECH INVESTMENT PARTNERSHIP, by its

partners,

	
	ANGIOTECH PHAMACEUTICALS, INC.
		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    SVP, Finance

	
	 3091796 NOVA SCOTIA COMPANY

		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    Director

			
	 ANGIOTECH PHARMACEUTICALS (US), INC.

		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    SVP, Finance

 

			
	 BG SULZLE, INC.

		
	 By:
	 	       /s/ David D. Phinney
        

		 	 Name:  David D. Phinney

Title:    Secretary

 

			
	 MANAN MEDICAL PRODUCTS, INC.

		
	 By:
	 	       /s/ David D. Phinney
        

		 	 Name:  David D. Phinney

Title:    Secretary

 

			
	 MEDICAL DEVICE TECHNOLOGIES, INC.

		
	 By:
	 	       /s/ David D. Phinney
        

		 	 Name:  David D. Phinney

Title:    Secretary

 

			
	 NEUCOLL, INC.

		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    Treasurer

 

			
	 QUILL MEDICAL, INC.

		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    Treasurer

			
	 SURGICAL SPECIALTIES CORPORATION

		
	 By:
	 	       /s/ David D. Phinney
        

		 	 Name:  David D. Phinney

Title:    Secretary

 

			
	 SURGICAL SPECIALTIES PUERTO RICO, INC.

		
	 By:
	 	       /s/ David D. Phinney
        

		 	 Name:  David D. Phinney

Title:    Secretary

 

			
	 SURGICAL SPECIALTIES UK HOLDINGS LIMITED

		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    Secretary

 

			
	 0741693 B.C. LTD.

		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    SVP, Finance

 

			
	 3091796 NOVA SCOTIA COMPANY

		
	 By:
	 	       /s/ Jay Dent         

		 	 Name:  Jay Dent

Title:    Director

 

			
	 DEUTSCHE BANK NATIONAL TRUST
COMPANY,
 as Trustee

		
	 By:
	 	       /s/ Katherine
Cohic        

		 	 Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]